Study Results Show Dose-Intensified Temozolomide Chemotherapy in the Adjuvant Setting Does Not Improve Survival in Patients with GBM
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
Apparently. the standard schedule is better than the dose intensive schedule for GBM patients using Temodar. However, what I would love to see is a trial comparing different lengths of treatment. This trial used up to 12 months of treatment. Overall survivals were about 6 months after they stopped using the Temodar in either arm. Doesn't make sense to me to stop at 1 year.
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines